header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

ORTHOPAEDIC ANTIMICROBIAL PROPHYLAXIS IN THE UNITED KINGDOM



Abstract

Introduction: Cephalosporins have traditionally been the preferred antimicrobial prophylaxis for 90% of orthopaedic surgeons. With a recent increase in Clos-tridium difficile and MRSA infections, antimicrobial prophylaxis is changing. The aim of this study was to conduct a national survey of current orthopaedic antimicrobial prophylaxis regimes. We wanted to ascertain whether there were any recent changes in these regimes and the reasons for these changes. We also aimed to show any relationship between antimicrobial usage and Clostridium difficile rates.

Methods: Information on prophylaxis regimes and Clostridium difficile rates was requested through a five item questionnaire which was sent to all hospitals in the United Kingdom.

Results: The response rate was 83 %. The top three antimicrobial regimes in trauma and elective orthopaedic surgery were cefuroxime alone (52 %), flucloxacillin plus gentamicin (18 %) and co-amoxiclav alone (8 %). Half of all hospitals had changed antimicrobial regimes and half of these changes were due to Clostridium difficile. The incidence of Clostridium difficile was 70% higher in hospitals using Cefuroxime than hospitals using other antibiotics (0.19% vs. 0.32%)(p < 0.001). Clostridium difficile infection was more common in trauma than elective surgery.

Conclusion: Cefuroxime is still the most commonly used antimicrobial agent but its use has declined mainly due to a surge in Clostridium difficile rates. Reduction in cephalosporin use along with other infection control measures has resulted in a fall in Clostridium difficile infection rates.

Correspondence should be addressed to: EFORT Central Office, Technoparkstrasse 1, CH – 8005 Zürich, Switzerland. Tel: +41 44 448 44 00; Email: office@efort.org

Author: Randeep Aujla, United Kingdom

E-mail: randeep.aujla@hotmail.co.uk